NEWS
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
Vigil Neuroscience (Nasdaq: VIGL) has announced promising interim data from its ongoing Phase 1 clinical trial of VG-3927, a potential once-daily oral therapy for Alzheimer's disease (AD).
The trial, which has enrolled 80 healthy volunteers, demonstrated a favorable safety and tolerability profile, with all adverse events being mild or moderate and resolving without intervention. Key findings include:
1. VG-3927 achieved a robust decrease in sTREM2 in cerebrospinal fluid, indicating clinical proof-of-target engagement.
2. The drug showed a predictable pharmacokinetic profile supporting once-daily dosing
.
3. An increase in osteopontin/SPP1, a biomarker associated with neuroprotective microglia, was observed after repeat dosing.
3. An increase in osteopontin/SPP1, a biomarker associated with neuroprotective microglia, was observed after repeat dosing.
Vigil plans to report complete Phase 1 data, including results from an AD patient cohort, in Q1 2025. The company will present new preclinical and clinical data at the upcoming 2024 Alzheimer's Association International Conference.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment